Illumina Stock Forecast, Price & News

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ILMN stock has increased by 42.5% and is now trading at $350.66.
View which stocks have been most impacted by COVID-19.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Illumina or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Illumina is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Illumina.

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Thursday, October, 29th. The life sciences company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.77 by $0.25. The life sciences company earned $794 million during the quarter, compared to the consensus estimate of $713.97 million. Illumina had a net margin of 19.70% and a return on equity of 15.93%. Illumina's quarterly revenue was down 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.93 EPS.
View Illumina's earnings history.

17 analysts have issued 12-month price targets for Illumina's stock. Their forecasts range from $280.00 to $400.00. On average, they expect Illumina's share price to reach $322.12 in the next twelve months. This suggests that the stock has a possible downside of 8.1%.
View analysts' price targets for Illumina.

Illumina saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,420,000 shares, an increase of 8.9% from the October 31st total of 4,060,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 3.0% of the shares of the stock are sold short.
View Illumina's Short Interest.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Waters (WAT), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (2.11%), Massachusetts Financial Services Co. MA (1.07%), Harding Loevner LP (1.01%), Jackson Square Partners LLC (0.87%), Sustainable Growth Advisers LP (0.81%) and ARK Investment Management LLC (0.67%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Jennison Associates LLC, First Hawaiian Bank, Nikko Asset Management Americas Inc., Sands Capital Management LLC, Natixis, Federated Hermes Inc., and Envestnet Asset Management Inc.. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina.

ILMN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Harding Loevner LP, Sarasin & Partners LLP, Arrowstreet Capital Limited Partnership, DAVENPORT & Co LLC, Sustainable Growth Advisers LP, Alleghany Corp DE, and Massachusetts Financial Services Co. MA.
View insider buying and selling activity for Illumina.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ILMN stock can currently be purchased for approximately $350.66.

Illumina has a market capitalization of $51.20 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

The official website for Illumina is www.illumina.com.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]